To further explore the appropriate biomarkers for different ICB treatments, we evaluated the correlations between these transcriptomic biomarkers and response in ten melanoma cohorts under different ICB therapy strategies including anti-PD-1, anti-CTLA-4, anti-PD-1 after progression on prior anti-CTLA-4 (anti-CTLA-4 prog anti-PD-1) and combined anti-PD-1 and anti-CTLA-4 immunotherapy (combination therapy) (Table 1). Here, CTLA4 is linked to melanoma.